

# Franco Trevisani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5455583/publications.pdf>

Version: 2024-02-01

135  
papers

8,428  
citations

44069

48  
h-index

48315

88  
g-index

136  
all docs

136  
docs citations

136  
times ranked

7797  
citing authors

#	ARTICLE	IF	CITATIONS
1	Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Meta-Analysis of Randomized Controlled Trials. <i>Radiology</i> , 2002, 224, 47-54.	7.3	784
2	Serum $\alpha$ -fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. <i>Journal of Hepatology</i> , 2001, 34, 570-575.	3.7	677
3	Diagnostic and Prognostic Role of alpha-Fetoprotein in Hepatocellular Carcinoma: Both or Neither?. <i>American Journal of Gastroenterology</i> , 2006, 101, 524-532.	0.4	391
4	Q-T interval prolongation in cirrhosis: Prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. <i>Hepatology</i> , 1998, 27, 28-34.	7.3	356
5	Semiannual and Annual Surveillance of Cirrhotic Patients for Hepatocellular Carcinoma: Effects on Cancer Stage and Patient Survival (Italian Experience). <i>American Journal of Gastroenterology</i> , 2002, 97, 734-744.	0.4	282
6	Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. <i>Journal of Hepatology</i> , 2010, 53, 291-297.	3.7	281
7	Prognosis of untreated hepatocellular carcinoma. <i>Hepatology</i> , 2015, 61, 184-190.	7.3	188
8	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study. <i>Journal of Hepatology</i> , 2015, 62, 617-624.	3.7	184
9	Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patient. <i>Cancer</i> , 1995, 75, 2220-2232.	4.1	155
10	Hepatocellular carcinoma in non-cirrhotic liver: A reappraisal. <i>Digestive and Liver Disease</i> , 2010, 42, 341-347.	0.9	155
11	Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2013, 45, 712-723.	0.9	155
12	Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. <i>Gut</i> , 2010, 59, 387-396.	12.1	145
13	Cardiac electrophysiological abnormalities in patients with cirrhosis. <i>Journal of Hepatology</i> , 2006, 44, 994-1002.	3.7	141
14	Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. <i>Journal of Hepatology</i> , 2019, 71, 265-273.	3.7	138
15	Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. <i>Lancet Oncology</i> , The, 2011, 12, 654-662.	10.7	135
16	Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. <i>Hepatology</i> , 2012, 56, 1371-1379.	7.3	130
17	Surveillance for Hepatocellular Carcinoma in Elderly Italian Patients With Cirrhosis: Effects on Cancer Staging and Patient Survival. <i>American Journal of Gastroenterology</i> , 2004, 99, 1470-1476.	0.4	116
18	Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. <i>PLoS Medicine</i> , 2016, 13, e1002006.	8.4	113

#	ARTICLE	IF	CITATIONS
19	Surveillance for Early Diagnosis of Hepatocellular Carcinoma: Is It Effective in Intermediate/Advanced Cirrhosis?. <i>American Journal of Gastroenterology</i> , 2007, 102, 2448-2457.	0.4	110
20	Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, 333-341.	3.7	110
21	Factors That Affect Efficacy of Ultrasound Surveillance for Early Stage Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1927-1933.e2.	4.4	108
22	Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy. <i>Hepatology</i> , 2020, 72, 2206-2218.	7.3	107
23	Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma â€” The SHELTER study. <i>Journal of Hepatology</i> , 2016, 65, 280-288.	3.7	98
24	Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment. <i>Liver Cancer</i> , 2017, 6, 16-26.	7.7	97
25	Renal sodium retention during upright posture in preascitic cirrhosis. <i>Gastroenterology</i> , 1993, 105, 188-193.	1.3	95
26	Hepatocellular Carcinoma Responding to Superselective Transarterial Chemoembolization: An Issue of Nodule Dimension?. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 509-517.	0.5	95
27	Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. <i>Hepatology</i> , 2018, 67, 1784-1796.	7.3	93
28	The hemodynamic status of preascitic cirrhosis: An evaluation under steady-state conditions and after postural change. <i>Hepatology</i> , 1992, 16, 341-346.	7.3	87
29	The changing scenario of hepatocellular carcinoma over the last two decades in Italy. <i>Journal of Hepatology</i> , 2012, 56, 397-405.	3.7	84
30	Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept. <i>Scientific Reports</i> , 2018, 8, 9997.	3.3	84
31	Effect of chronic $\beta^2$ -blockade on QT interval in patients with liver cirrhosis. <i>Journal of Hepatology</i> , 2008, 48, 415-421.	3.7	83
32	Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 67, 65-71.	3.7	83
33	Effect of the Etiology of Viral Cirrhosis on the Survival of Patients with Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2006, 101, 91-98.	0.4	81
34	Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. <i>BMC Cancer</i> , 2009, 9, 33.	2.6	79
35	Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it?. <i>World Journal of Gastroenterology</i> , 2013, 19, 8808.	3.3	72
36	A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 1157-1166.	3.9	70

#	ARTICLE	IF	CITATIONS
37	Prevalence and Prognostic Significance of the Presence of Esophageal Varices in Patients With Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1378-1384.	4.4	69
38	The changing scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2021, 41, 585-597.	3.9	69
39	QT Interval Correction in Patients with Cirrhosis. <i>Journal of Cardiovascular Electrophysiology</i> , 2007, 18, 77-82.	1.7	67
40	The evolutionary scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2017, 37, 259-270.	3.9	67
41	Metronomic Capecitabine in Advanced Hepatocellular Carcinoma Patients: A Phase II Study. <i>Oncologist</i> , 2013, 18, 1256-1257.	3.7	64
42	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 593-604.	12.1	62
43	Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. <i>Journal of Hepatology</i> , 2012, 56, 1089-1096.	3.7	61
44	Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2016, 111, 70-77.	0.4	59
45	Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. <i>British Journal of Cancer</i> , 2016, 115, 297-302.	6.4	58
46	Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 38-51.	7.7	58
47	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. <i>Gut</i> , 2023, 72, 141-152.	12.1	57
48	Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use. <i>Cancer</i> , 2014, 120, 2150-2157.	4.1	56
49	Impact of Etiology of Cirrhosis on the Survival of Patients Diagnosed With Hepatocellular Carcinoma During Surveillance. <i>CME. American Journal of Gastroenterology</i> , 2007, 102, 1022-1031.	0.4	54
50	Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification. <i>Liver Cancer</i> , 2019, 8, 78-91.	7.7	53
51	Is female sex a significant favorable prognostic factor in hepatocellular carcinoma?. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 1212-1218.	1.6	51
52	Hepatocellular Carcinoma in Patients With Cryptogenic Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 580-585.	4.4	48
53	QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. <i>Liver International</i> , 2012, 32, 1510-1515.	3.9	48
54	Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. <i>Liver International</i> , 2013, 33, 1594-1600.	3.9	46

#	ARTICLE	IF	CITATIONS
55	Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2016, 48, 798-805.	0.9	46
56	Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 423-433.	3.9	46
57	Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 403-414.	2.5	45
58	Alpha-fetoprotein for Diagnosis, Prognosis, and Transplant Selection. <i>Seminars in Liver Disease</i> , 2019, 39, 163-177.	3.6	45
59	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. <i>Cancers</i> , 2019, 11, 1689.	3.7	44
60	BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. <i>Liver International</i> , 2015, 35, 223-231.	3.9	41
61	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. <i>Liver International</i> , 2019, 39, 1478-1489.	3.9	41
62	Association of Abnormal Plasma Bilirubin With Aggressive Hepatocellular Carcinoma Phenotype. <i>Seminars in Oncology</i> , 2014, 41, 252-258.	2.2	40
63	Hepatocellular carcinoma in patients without cirrhosis in Italy. <i>Digestive and Liver Disease</i> , 2013, 45, 164-169.	0.9	38
64	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 859-871.	1.7	38
65	Significance of Platelet and AFP Levels and Liver Function Parameters for HCC Size and Survival. <i>International Journal of Biological Markers</i> , 2014, 29, 215-223.	1.8	36
66	Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 296-304.	1.6	36
67	Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 370-379.	7.7	31
68	A Liver Index and its Relationship to Indices of HCC Aggressiveness. <i>Journal of Integrative Oncology</i> , 2016, 5, .	0.3	28
69	De novo hepatocellular carcinoma of liver allograft: A neglected issue. <i>Cancer Letters</i> , 2015, 357, 47-54.	7.2	27
70	Osteonecrosis of the Jaw during Sorafenib Therapy for Hepatocellular Carcinoma. <i>Tumori</i> , 2016, 102, S69-S70.	1.1	26
71	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. <i>Hepatology</i> , 2018, 68, 1232-1244.	7.3	26
72	Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2022, 275, 743-752.	4.2	24

#	ARTICLE	IF	CITATIONS
73	Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. <i>Digestive and Liver Disease</i> , 2011, 43, 875-80.	0.9	23
74	Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients. <i>International Journal of Biological Markers</i> , 2018, 33, 423-431.	1.8	23
75	Low Alpha-Fetoprotein HCC and the Role of GGTP. <i>International Journal of Biological Markers</i> , 2014, 29, 395-402.	1.8	21
76	Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. <i>Cancers</i> , 2021, 13, 1673.	3.7	21
77	Systemic and regional hemodynamics in pre-ascitic cirrhosis: effects of posture. <i>Journal of Hepatology</i> , 2003, 39, 502-508.	3.7	20
78	Efficacy of radioembolization according to tumor morphology and portal vein thrombosis in intermediate-advanced hepatocellular carcinoma. <i>Future Oncology</i> , 2015, 11, 3133-3142.	2.4	20
79	Length time bias in surveillance for hepatocellular carcinoma and how to avoid it. <i>Hepatology Research</i> , 2016, 46, 1275-1280.	3.4	20
80	Lipiodol transarterial chemoembolization for hepatocellular carcinoma: Where are we now?. <i>Hepatology</i> , 2016, 64, 23-25.	7.3	19
81	Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria. <i>Scientific Reports</i> , 2019, 9, 3781.	3.3	18
82	Pattern of macrovascular invasion in hepatocellular carcinoma. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13542.	3.4	18
83	Development and Validation of a Scoring System That Includes Corrected QT Interval for Risk Analysis of Patients With Cirrhosis and Gastrointestinal Bleeding. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1388-1397.e1.	4.4	16
84	Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?. <i>Vaccines</i> , 2020, 8, 578.	4.4	16
85	Liver transplantation for hepatocellular carcinoma in clinical practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 195-202.	1.6	15
86	Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis. <i>BMC Cancer</i> , 2018, 18, 715.	2.6	15
87	Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00286.	2.5	15
88	Identification of Two Clinical Hepatocellular Carcinoma Patient Phenotypes From Results of Standard Screening Parameters. <i>Seminars in Oncology</i> , 2014, 41, 406-414.	2.2	14
89	Art in the Hospital: Its Impact on the Feelings and Emotional State of Patients Admitted to an Internal Medicine Unit. <i>Journal of Alternative and Complementary Medicine</i> , 2010, 16, 853-859.	2.1	13
90	Effectiveness of $\alpha$ -fetoprotein for hepatocellular carcinoma surveillance: the return of the living-dead?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 441-444.	3.0	13

#	ARTICLE	IF	CITATIONS
91	Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA-LI-CA centres. <i>Liver International</i> , 2013, 33, 1420-1427.	3.9	13
92	Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. <i>Journal of Clinical Medicine</i> , 2021, 10, 3201.	2.4	13
93	Beneficial Prognostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders. <i>Cancers</i> , 2021, 13, 6376.	3.7	13
94	Alpha-fetoprotein in hepatocellular carcinoma surveillance: Wake not the dead. <i>Hepatology</i> , 2011, 54, 376-377.	7.3	10
95	Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor. <i>Liver Transplantation</i> , 2015, 21, 1250-1258.	2.4	10
96	Metabolic disorders across hepatocellular carcinoma in Italy. <i>Liver International</i> , 2018, 38, 2028-2039.	3.9	10
97	Monofocal hepatocellular carcinoma: How much does size matter?. <i>Liver International</i> , 2021, 41, 396-407.	3.9	10
98	Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. <i>Cancers</i> , 2021, 13, 897.	3.7	9
99	Relative decrease in the role played by hepatitis B virus infection in the aetiology of hepatocellular carcinoma during a 20-year period: a multicentre Italian study. <i>Liver International</i> , 2011, 31, 192-196.	3.9	8
100	Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter. <i>International Journal of Biological Markers</i> , 2021, 36, 54-61.	1.8	8
101	Daily profile of circulating C-type natriuretic peptide in pre-ascitic cirrhosis and in normal subjects: Relationship with renal function. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 642-647.	1.5	7
102	Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. <i>Digestive and Liver Disease</i> , 2013, 45, 516-522.	0.9	7
103	Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients. <i>Digestive and Liver Disease</i> , 2018, 50, 156-162.	0.9	7
104	Prognostic Role of Bacterial and Fungal Infections in Patients With Liver Cirrhosis With and Without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa453.	0.9	7
105	Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2600-2608.e1.	4.4	7
106	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study. <i>Digestive and Liver Disease</i> , 2021, 53, 1011-1019.	0.9	7
107	Treatment allocation in patients with hepatocellular carcinoma: Need for a paradigm shift?. <i>Liver Cancer International</i> , 2022, 3, 34-36.	1.3	7
108	Prognostic indicators in patients with cirrhosis and hepatocellular carcinoma undergoing surgical resection. <i>Journal of Surgical Oncology</i> , 1993, 53, 67-69.	1.7	6

#	ARTICLE	IF	CITATIONS
109	Ten-Year Outcome of Radiofrequency Thermal Ablation for Hepatocellular Carcinoma: An Italian Experience. <i>American Journal of Gastroenterology</i> , 2012, 107, 1588-1589.	0.4	6
110	Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score Analysis. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1015-1024.	2.0	6
111	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Liver Cancer</i> , 2021, 10, 126-136.	7.7	6
112	A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study. <i>Cancers</i> , 2021, 13, 2677.	3.7	6
113	Transarterial chemoembolization in Child-Pugh class B patients with hepatocellular carcinoma: between the devil and the deep blue sea. <i>Liver International</i> , 2010, 30, 923-924.	3.9	5
114	Surveillance for Hepatocellular Carcinoma: Just Do It!. <i>American Journal of Gastroenterology</i> , 2013, 108, 1013-1014.	0.4	5
115	Improving survival of cirrhosis patients with hepatocellular carcinoma through application of standard of care. <i>Hepatology</i> , 2014, 60, 1446-1447.	7.3	5
116	Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs. <i>Cancers</i> , 2021, 13, 592.	3.7	5
117	Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 822507.	2.8	5
118	Prognostication of the outcome of hepatocellular carcinoma: How to rely on science instead of on the art of Nostradamus. <i>Digestive and Liver Disease</i> , 2009, 41, 382-384.	0.9	4
119	Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. <i>Digestive and Liver Disease</i> , 2022, 54, 927-936.	0.9	4
120	Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. <i>European Journal of Cancer</i> , 2021, 158, 133-143.	2.8	4
121	Is it time to extend criteria for hepatic resection in the treatment of hepatocellular carcinoma?. <i>Hepatology</i> , 2016, 64, 2257-2258.	7.3	3
122	Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2022, 54, 1215-1221.	0.9	3
123	Accuracy of $\alpha$ -Fetoprotein Measurement in Detection of Hepatocellular Carcinoma "1 More Nail in the Coffin. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 2138-2139.	4.4	2
124	Screening for Hepatocellular Carcinoma in Chronic Liver Disease. <i>Annals of Internal Medicine</i> , 2015, 162, 239.	3.9	2
125	Reply to: "Sorafenib or <sup>90</sup> Y loaded resin microsphere radioembolization for locally advanced hepatocellular carcinoma, what should we trust?". <i>Liver International</i> , 2015, 35, 1780-1781.	3.9	2
126	Recalibrating survival prediction among patients receiving transarterial chemoembolization for hepatocellular carcinoma. <i>Liver Cancer International</i> , 2021, 2, 45-53.	1.3	2



#	ARTICLE	IF	CITATIONS
127	Ablation and resection for hepatocellular carcinoma within Milan criteria and high alpha-fetoprotein levels. <i>Liver International</i> , 2016, 36, 1877-1877.	3.9	1
128	Response to Intermediate stage treatment: Is TACE enough?. <i>Liver International</i> , 2018, 38, 188-189.	3.9	1
129	Ramucirumab as a second-line treatment for hepatocellular carcinoma: reaching out further to patients with elevated alpha-fetoprotein. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 515-518.	1.5	1
130	Liver Resection for Patients with Intermediate Stage Hepatocellular Carcinoma: Beyond Rigid Staging Systems Towards a More Personalized Therapeutic Approach. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1078-1079.	1.7	1
131	Is the Strongest Level of Medical Evidence Always Required for Guidelines Recommendations?. <i>Liver Cancer</i> , 2021, 10, 1-2.	7.7	1
132	The ITA.LI.CA Consortium: how multicentre collaboration helped shape the management of patients with hepatocellular carcinoma on the basis of real-world evidence.. <i>Annals of Hepatology</i> , 2021, , 100564.	1.5	1
133	Letter: is female sex really associated with better prognosis in hepatocellular carcinoma?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 669-670.	3.7	1
134	Reply. <i>Hepatology</i> , 2019, 69, 465-466.	7.3	0
135	Time to move beyond the classical prognostic systems for patients with advanced hepatocellular carcinoma undergoing Sorafenib. <i>Digestive and Liver Disease</i> , 2021, 53, 1210-1211.	0.9	0